Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A.L. Catapano is active.

Publication


Featured researches published by A.L. Catapano.


European Heart Journal | 2013

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

Børge G. Nordestgaard; M.J. Chapman; S.E. Humphries; Henry N. Ginsberg; Luis Masana; Olivier S. Descamps; Olov Wiklund; Robert A. Hegele; Frederick J. Raal; J.C. Defesche; Albert Wiegman; R.D.D. Santos; Gerald F. Watts; Klaus G. Parhofer; G.K. Hovingh; Petri T. Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; A.L. Catapano; Jan Albert Kuivenhoven; P.E. Pajukanta; Kausik K. Ray; Anton F. H. Stalenhoef; E.S.G. Stroes; M.-R. Taskinen; Anne Tybjærg-Hansen

Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD). Methods and results Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prevalences between 1/500 and 1/200, between 14 and 34 million individuals worldwide have FH. We recommend that children, adults, and families should be screened for FH if a person or family member presents with FH, a plasma cholesterol level in an adult ≥8 mmol/L(≥310 mg/dL) or a child ≥6 mmol/L(≥230 mg/dL), premature CHD, tendon xanthomas, or sudden premature cardiac death. In FH, low-density lipoprotein cholesterol targets are <3.5 mmol/L(<135 mg/dL) for children, <2.5 mmol/L(<100 mg/dL) for adults, and <1.8 mmol/L(<70 mg/dL) for adults with known CHD or diabetes. In addition to lifestyle and dietary counselling, treatment priorities are (i) in children, statins, ezetimibe, and bile acid binding resins, and (ii) in adults, maximal potent statin dose, ezetimibe, and bile acid binding resins. Lipoprotein apheresis can be offered in homozygotes and in treatment-resistant heterozygotes with CHD. Conclusion Owing to severe underdiagnosis and undertreatment of FH, there is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition.


European Heart Journal | 2015

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

Albert Wiegman; Samuel S. Gidding; Gerald F. Watts; M.J. Chapman; Henry N. Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; A.L. Catapano; Joep C. Defesche; Olivier S. Descamps; Robert A. Hegele; G.K. Hovingh; S.E. Humphries; Petri T. Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G. Nordestgaard; Päivi Pajukanta; Klaus G. Parhofer; Frederick J. Raal; Kausik K. Ray; Raul D. Santos; Anton F. H. Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S.G. Stroes; Marja-Riitta Taskinen

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testing. Childhood is the optimal period for discrimination between FH and non-FH using LDL-C screening. An LDL-C ≥5 mmol/L (190 mg/dL), or an LDL-C ≥4 mmol/L (160 mg/dL) with family history of premature CHD and/or high baseline cholesterol in one parent, make the phenotypic diagnosis. If a parent has a genetic defect, the LDL-C cut-off for the child is ≥3.5 mmol/L (130 mg/dL). We recommend cascade screening of families using a combined phenotypic and genotypic strategy. In children, testing is recommended from age 5 years, or earlier if homozygous FH is suspected. A healthy lifestyle and statin treatment (from age 8 to 10 years) are the cornerstones of management of heterozygous FH. Target LDL-C is <3.5 mmol/L (130 mg/dL) if >10 years, or ideally 50% reduction from baseline if 8–10 years, especially with very high LDL-C, elevated lipoprotein(a), a family history of premature CHD or other cardiovascular risk factors, balanced against the long-term risk of treatment side effects. Identifying FH early and optimally lowering LDL-C over the lifespan reduces cumulative LDL-C burden and offers health and socioeconomic benefits. To drive policy change for timely detection and management, we call for further studies in the young. Increased awareness, early identification, and optimal treatment from childhood are critical to adding decades of healthy life for children and adolescents with FH.


BMC Medical Informatics and Decision Making | 2017

Automatic identification of variables in epidemiological datasets using logic regression

Matthias W. Lorenz; Negin Ashtiani Abdi; Frank Scheckenbach; Anja Pflug; Alpaslan Bülbül; A.L. Catapano; Stefan Agewall; M. Ezhov; Michiel L. Bots; Stefan Kiechl; Andreas Orth; Giuseppe Danilo Norata; Jean Philippe Empana; Hung Ju Lin; Stela McLachlan; Lena Bokemark; Kimmo Ronkainen; Mauro D’Amato; Ulf Schminke; Lars Lind; Akihiko Kato; Chrystosomos Dimitriadis; Tadeusz Przewlocki; Shuhei Okazaki; Coen D. A. Stehouwer; Tatjana Lazarevic; Peter Willeit; David Yanez; Helmuth Steinmetz; Dirk Sander

BackgroundFor an individual participant data (IPD) meta-analysis, multiple datasets must be transformed in a consistent format, e.g. using uniform variable names. When large numbers of datasets have to be processed, this can be a time-consuming and error-prone task. Automated or semi-automated identification of variables can help to reduce the workload and improve the data quality. For semi-automation high sensitivity in the recognition of matching variables is particularly important, because it allows creating software which for a target variable presents a choice of source variables, from which a user can choose the matching one, with only low risk of having missed a correct source variable.MethodsFor each variable in a set of target variables, a number of simple rules were manually created. With logic regression, an optimal Boolean combination of these rules was searched for every target variable, using a random subset of a large database of epidemiological and clinical cohort data (construction subset). In a second subset of this database (validation subset), this optimal combination rules were validated.ResultsIn the construction sample, 41 target variables were allocated on average with a positive predictive value (PPV) of 34%, and a negative predictive value (NPV) of 95%. In the validation sample, PPV was 33%, whereas NPV remained at 94%. In the construction sample, PPV was 50% or less in 63% of all variables, in the validation sample in 71% of all variables.ConclusionsWe demonstrated thatxa0the application of logic regression in a complex data management task in large epidemiological IPD meta-analyses is feasible. However, the performance of the algorithm is poor, which may require backup strategies.


Atherosclerosis Supplements | 2009

Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008.

V. Atella; A. Brady; A.L. Catapano; J. Critchley; Ian Graham; F.D.R. Hobbs; J. Leal; Peter Lindgren; Diego Vanuzzo; Massimo Volpe; D. Wood; Rodolfo Paoletti


International Journal of Stroke | 2014

Inflammatory markers and extent and progression of early atherosclerosis: Pooled analysis of individual participant data from 20 prospective studies of the PROG-IMT collaboration

Peter Willeit; Simon G. Thompson; Stefan Agewall; Göran Bergström; Horst Bickel; A.L. Catapano; Kuo-Liong Chien; E. de Groot; Jean Philippe Empana; T. Etgen; Oscar H. Franco; Bernhard Iglseder; Stein Harald Johnsen; Maryam Kavousi; Lars Lind; Jing Liu; Ellisiv B. Mathiesen; Giuseppe Danilo Norata; M. H. Olsen; Aikaterini Papagianni; Holger Poppert; Jackie F. Price; Ralph L. Sacco; David Yanez; Di Zhao; Ulf Schminke; A. Buelbuel; Joseph F. Polak; Albert Hofman; Liliana Grigore


European Heart Journal | 2018

5206PCSK9 deficiency results in altered insulin secretion and glucose intolerance: the role of the LDL-receptor

L Da Dalt; G. Balzarotti; Massimiliano Ruscica; Fabrizia Bonacina; Chiara Macchi; Carla Perego; A.L. Catapano; Giuseppe Danilo Norata


Atherosclerosis | 2018

The PCSK9/LDLR axis impacts insulin secretion and glucose response

L. Da Dalt; G. Balzarotti; Massimiliano Ruscica; Fabrizia Bonacina; A. Dhyani; E. Di Cairano; Andrea Baragetti; Lorenzo Arnaboldi; S. De Metrio; Chiara Macchi; Margherita Botta; Patrizia Uboldi; Carla Perego; A.L. Catapano; Giuseppe Danilo Norata


Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır | 2015

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

Marina Cuchel; Eric Bruckert; Henry N. Ginsberg; Raal Fj; Raul D. Santos; Robert A. Hegele; Jan Albert Kuivenhoven; Børge G. Nordestgaard; Olivier S. Descamps; Elisabeth Steinhagen-Thiessen; Anne Tybjærg-Hansen; Gerald F. Watts; Maurizio Averna; Catherine Boileau; Jan Borén; A.L. Catapano; Joep C. Defesche; G.K. Hovingh; S.E. Humphries; Petri T. Kovanen; Luis Masana; Päivi Pajukanta; Parhofer Kg; Kausik K. Ray; Anton F. H. Stalenhoef; E.S.G. Stroes; Marja-Riitta Taskinen; Albert Wiegman; Olov Wiklund; M.J. Chapman


International Journal of Stroke | 2014

Inflammatory markers and extent and progression of early atherosclerosis

Peter Willeit; Simon G. Thompson; Stefan Agewall; Göran Bergström; Horst Bickel; A.L. Catapano; Kuo-Liong Chien; E. de Groot; Jean Philippe Empana; T. Etgen; Oscar H. Franco; Bernhard Iglseder; Stein Harald Johnsen; Maryam Kavousi; Lars Lind; Jing Liu; Ellisiv B. Mathiesen; Giuseppe Danilo Norata; Michael H. Olsen; Aikaterini Papagianni; Holger Poppert; Jackie F. Price; Ralph L. Sacco; David Yanez; Di Zhao; Ulf Schminke; A. Buelbuel; Joseph F. Polak; Albert Hofman; Liliana Grigore


Atherosclerosis Supplements | 2011

32 TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT

M.J. Chapman; Henry N. Ginsberg; P. Amarenco; F. Andreotti; Jan Borén; A.L. Catapano; Olivier S. Descamps; E. Fisher; Petri T. Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; B.G. Nordestgaard; Kausik K. Ray; Z. Reiner; Marja-Riitta Taskinen; Lale Tokgozoglu; Anne Tybjærg-Hansen; Gerald F. Watts

Collaboration


Dive into the A.L. Catapano's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Borén

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gerald F. Watts

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Olivier S. Descamps

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S.E. Humphries

University College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge